Enanta Pharmaceuticals, Inc
ENTA Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
ENTA Income Statement
ENTA Balance Sheet
ENTA Cash Flow
Recent trades of ENTA by members of U.S. Congress
ENTA Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
ENTA Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
ENTA Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ENTA's directors and management
Government lobbying spending instances
-
$20,000 Nov 14, 2023 Issue: Health Issues
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Hepatitis b antiviral agents Aug. 06, 2024
-
Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Jun. 25, 2024
-
Patent Title: Hepatitis b antiviral agents Jun. 18, 2024
-
Patent Title: Antiviral heterocyclic compounds Jun. 11, 2024
-
Patent Title: Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid Jun. 11, 2024
-
Patent Title: Saturated spirocyclics as antiviral agents May. 28, 2024
-
Patent Title: Spiropyrrolidine derived antiviral agents May. 07, 2024
-
Patent Title: Macrocyclic antiviral agents Apr. 30, 2024
-
Patent Title: Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof Apr. 16, 2024
-
Patent Title: Benzodiazepine derivatives as rsv inhibitors Apr. 09, 2024
-
Patent Title: Antiviral heterocyclic compounds Apr. 02, 2024
-
Patent Title: Heterocyclic compounds as anti-viral agents Apr. 02, 2024
-
Patent Title: Spiropyrrolidine derived antiviral agents Mar. 05, 2024
-
Patent Title: Spiropyrrolidine derived antiviral agents Feb. 27, 2024
-
Patent Title: Benzodiazepine derivatives as rsv inhibitors Feb. 27, 2024
-
Patent Title: Functionalized heterocycles as antiviral agents Feb. 06, 2024
-
Patent Title: Alkyne-containing antiviral agents Jan. 02, 2024
-
Patent Title: Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Dec. 05, 2023
-
Patent Title: Hepatitis b antiviral agents Sep. 19, 2023
-
Patent Title: Substituted heterocycles as antiviral agents Aug. 29, 2023
-
Patent Title: Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof Aug. 08, 2023
-
Patent Title: Hepatitis b antiviral agents Mar. 07, 2023
-
Patent Title: Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof Feb. 14, 2023
-
Patent Title: Antiviral heterocyclic compounds Feb. 07, 2023
-
Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof Jan. 24, 2023
-
Patent Title: Isoxazole derivatives as fxr agonists and methods of use thereof Jan. 17, 2023
-
Patent Title: Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors Dec. 27, 2022
-
Patent Title: Antiviral heterocyclic compounds Nov. 22, 2022
-
Patent Title: Substituted pyrrolo[1,2-c]pyrimidines as hepatitis b antiviral agents Oct. 18, 2022
-
Patent Title: Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors Oct. 11, 2022
-
Patent Title: Heterocyclic compounds as anti-viral agents Aug. 23, 2022
-
Patent Title: Benzodiazepine derivatives as rsv inhibitors Jul. 19, 2022
-
Patent Title: Spiropyrrolidine derived antiviral agents Jul. 12, 2022
-
Patent Title: Functionalized heterocycles as antiviral agents Jul. 05, 2022
-
Patent Title: Functionalized peptides as antiviral agents Jun. 14, 2022
-
Patent Title: Spiropyrrolidine derived antiviral agents Jun. 07, 2022
-
Patent Title: Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof May. 31, 2022
-
Patent Title: Spiropyrrolidine derived antiviral agents May. 24, 2022
-
Patent Title: Spiropyrrolidine derived antiviral agents May. 10, 2022
-
Patent Title: Macrocyclic spiropyrrolidine derived antiviral agents May. 03, 2022
-
Patent Title: Benzodiazepine derivatives as rsv inhibitors Feb. 22, 2022
-
Patent Title: Hepatitis b antiviral agents Feb. 01, 2022
-
Patent Title: Functionalized heterocycles as antiviral agents Feb. 01, 2022
-
Patent Title: Functionalized heterocycles as antiviral agents Dec. 14, 2021
-
Patent Title: Heterocyclic compounds as rsv inhibitors Nov. 23, 2021
-
Patent Title: Heterocyclic compounds as rsv inhibitors Aug. 17, 2021
-
Patent Title: Substituted heterocycles as antiviral agents Jul. 13, 2021
-
Patent Title: Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof Jun. 22, 2021
-
Patent Title: Isoxazole analogs as fxr agonists and methods of use thereof Jun. 15, 2021
-
Patent Title: Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof May. 18, 2021
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of ENTA in WallStreetBets Daily Discussion
ENTA News
Recent insights relating to ENTA
CNBC Recommendations
Recent picks made for ENTA stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ENTA
ENTA Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ENTA Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More